<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05065671</url>
  </required_header>
  <id_info>
    <org_study_id>Pro2021000945</org_study_id>
    <nct_id>NCT05065671</nct_id>
  </id_info>
  <brief_title>Microbiome Derived Metabolism and Pharmacokinetics</brief_title>
  <acronym>MDM-PK</acronym>
  <official_title>Incorporating Drug Metabolism by the Human Gut Microbiome Into Personalized Medicine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will perform single-dose pharmacokinetic (PK) studies in humans following&#xD;
      administration of drugs with known microbiome derived metabolism (MDM) in parallel with&#xD;
      preclinical studies. By directly comparing laboratory measurements to clinical results, the&#xD;
      investigators will be able to confirm the relevance of MDM in vivo, create&#xD;
      microbiome-dependent PK profiles of the MDM positive drugs, and establish methodology to&#xD;
      capture the contribution of MDM to inter-individual variability in clinical drug PK profiles.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The human gut microbiome has been shown to play an important role in the observed&#xD;
      inter-individual variability in therapeutic response, including both efficacy and toxicity.&#xD;
      One of the mechanisms by which the gut microbiome exerts these effects is through the direct&#xD;
      biochemical transformation of orally administered drugs into more or less active or toxic&#xD;
      metabolites, termed herein microbiome-derived drug metabolism (MDM). Recent systematic&#xD;
      studies have revealed an enormous and largely unexplored biochemical capacity of human gut&#xD;
      bacteria - cultured in ex vivo microbial communities or as single isolates - to metabolize&#xD;
      dozens of orally administered drugs but the clinical relevance of the observed MDM remains&#xD;
      unmapped. This gap in knowledge is a result of overt disconnect between preclinical and&#xD;
      clinical studies: MDM studies performed in the laboratory are removed from direct clinical&#xD;
      comparisons, and human studies performed during drug development and therapeutic&#xD;
      interventions almost completely ignore microbiome contribution. Moreover, there is currently&#xD;
      a lack standardized experimental methods and mathematical models to start incorporating MDM&#xD;
      into clinical decisions. Our PK studies are aimed at developing such strategies into clinical&#xD;
      practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>After a single dose of a microbiome derived metabolism positive drug (over an 8 hour period for each drug)</time_frame>
    <description>We will calculate the plasma area under the curve for the microbiome derived metabolism positive probe drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug peak plasma concentration</measure>
    <time_frame>After a single dose of a microbiome derived metabolism positive drug (over an 8 hour period for each drug)</time_frame>
    <description>We will measure the peak plasma concentration for microbiome derived metabolism positive probe drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug trough plasma concentrations</measure>
    <time_frame>After a single dose of a microbiome derived metabolism positive drug (over an 8 hour period for each drug)</time_frame>
    <description>We will measure the trough plasma concentration for microbiome derived metabolism positive probe drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug volume of distribution</measure>
    <time_frame>After a single dose of a microbiome derived metabolism positive drug (over an 8 hour period for each drug)</time_frame>
    <description>We will calculate the volume of distribution for microbiome derived metabolism positive probe drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug half-life</measure>
    <time_frame>After a single dose of a microbiome derived metabolism positive drug (over an 8 hour period for each drug)</time_frame>
    <description>We will calculate drug half-life for microbiome derived metabolism positive probe drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug plasma clearance</measure>
    <time_frame>After a single dose of a microbiome derived metabolism positive drug (over an 8 hour period for each drug)</time_frame>
    <description>We will calculate drug plasma clearance for each microbiome derived metabolism positive drug.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Quantitation of microbiome derived metabolism positive drug metabolites in urine</measure>
    <time_frame>After a single dose of a microbiome derived metabolism positive drug (over an 8 hour period for each drug)</time_frame>
    <description>The concentration of microbiome derived metabolism positive drug metabolites in urine will be measured</description>
  </other_outcome>
  <other_outcome>
    <measure>Quantitation of microbiome derived metabolism positive drugs in urine</measure>
    <time_frame>After a single dose of a microbiome derived metabolism positive drug (over an 8 hour period for each drug)</time_frame>
    <description>The concentration of microbiome derived metabolism positive drugs in urine will be measured.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Microbial Colonization</condition>
  <arm_group>
    <arm_group_label>Tolcapone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tolcapone 100 mg by mouth once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duloxetine 30 mg by mouth once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolcapone 100 MG</intervention_name>
    <description>Tolcapone 100 mg by mouth once</description>
    <arm_group_label>Tolcapone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine 30 MG</intervention_name>
    <description>Duloxetine 30 mg by mouth once</description>
    <arm_group_label>Duloxetine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 65 years of age&#xD;
&#xD;
          -  Body mass index between 18.5 - 25.0 kg/m2&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Estimated creatinine clearance &lt; 50 mL/min&#xD;
&#xD;
          -  Liver impairment (liver enzymes &gt; 2 times upper limit)&#xD;
&#xD;
          -  Antibiotics in the past 3 months&#xD;
&#xD;
          -  History of gastrointestinal disease&#xD;
&#xD;
          -  History of autoimmune disorder&#xD;
&#xD;
          -  Chronic viral infection&#xD;
&#xD;
          -  Smoker&#xD;
&#xD;
          -  Alcohol intake (defined as having up to 1 drink per day for women and up to 2 drinks&#xD;
             per day for men)&#xD;
&#xD;
          -  Use of immune modulating medications&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Any history or contraindication to the study medications&#xD;
&#xD;
          -  Additional exclusion criteria will be based on the FDA approved prescribing&#xD;
             information for selected drugs (i.e., contraindications)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Luigi Brunetti, PhD</last_name>
    <phone>908-595-2645</phone>
    <email>luigi.brunetti@rutgers.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed Donia, PhD</last_name>
    <phone>609-258-5870</phone>
    <email>donia@princeton.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Robert Wood Johnson University Hospital Somerset</name>
      <address>
        <city>Somerville</city>
        <state>New Jersey</state>
        <zip>08876</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers, The State University of New Jersey</investigator_affiliation>
    <investigator_full_name>Luigi Brunetti, PharmD, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Tolcapone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

